Jimin Healthcare (603222): The high base of the previous epidemic has been digested, and performance is expected to take off in 23
Jimin Medical (603222): Domestic consumables and medical service business is expected to achieve rapid growth
Jimin Medical (603222) 2022 Report Review: Performance is in line with expectations, and the company is optimistic that the company will reach an inflection point in '23
Jimin Healthcare (603222): High-end medical services such as Boao Hospital with high policy barriers and new technology start a second growth curve
Jimin Medical (603222) Company's First Coverage Report: Continued Release of Safety Syringes at Boao International Hospital Turned Loss into Profit
[Guohai Securities] Jimin Pharmaceutical Incident Review: The Medical Service Layout Is Next City, Demonstrating the Ability to Integrate Medical Service Resources
Jimin Pharmaceutical (603222) Review: The medical service layout in the next city highlights the ability to integrate medical service resources
Jimin Pharmaceutical (603222) Interim Report Review: Long-term optimism about high-end infusions and in-depth cooperation with Jiuding
[Ping An Securities] Jimin Pharmaceutical: Regional Infusion Leader with Steady Growth
[Shanghai Securities] Jimin Pharmaceutical: a regional manufacturer of large infusion and characteristic syringes
[northeast Securities] Jimin Pharmaceutical: across the two major fields of large infusion and injection puncture medical devices
[Haitong] Jimin Pharmaceutical: an infusion enterprise ready to enter the field of hemodialysis
[Shen Wan Hongyuan] Jimin Pharmaceutical: a regional high-end large infusion leading enterprise, the advantage of the whole industry chain of drug packaging materials is beginning to show.
Jimin Pharmaceutical (603222) IPO Analysis: Leading Regional High-End Infusion Companies Are Beginning to Show Their Advantages in the Pharmaceutical Packaging Materials Industry Chain
济民制药(603222):区域性高端大输液领先企业 药包材全产业链优势初显
[Cathay Pacific Junan Securities] Small and Medium Cap IPO Company Report - Jimin Pharmaceutical: Jimin Pharmaceutical's IPO Strategy
No Data
No Data